biopharma-reporter3h
Sarepta discontinues development of Duchenne ASO treatment vesleteplirsen
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...
biopharma-reporter7h
Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases
The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...